Kodiak Sciences stocks jump following successful eye drug study

• Patients on Zenkuda saw an 85% reduction in risk of developing sight-threatening complications such as proliferative diabetic retinopathy
• The drug was well tolerated with no reported cases of vision-threatening conditions like blood vessel or eye inflammation
• Zenkuda demonstrated consistent efficacy regardless of whether patients were taking GLP-1 medications

Kodiak Sciences Stock Surges on Positive Eye Drug Trial Results

Kodiak Sciences shares jumped 52% in pre-market trading on March 26 following successful late-stage clinical trial results for its experimental drug Zenkuda, designed to treat diabetic retinopathy. The company, valued at $1.39 billion as of the previous close, announced the drug met its primary endpoint in treating this diabetes-related eye complication.

Key Trial Results:

• 62.5% of patients receiving Zenkuda achieved at least a two-step improvement on the standard retinopathy severity scale at 48 weeks, compared to just 3.3% in the placebo group
• Patients demonstrated an 85% reduction in risk of developing sight-threatening complications, including progression to proliferative diabetic retinopathy
• The drug was well tolerated with no reported cases of vision-threatening conditions such as blood vessel inflammation or eye inflammation

Drug Profile:

Zenkuda is a long-acting treatment designed to block a protein associated with harmful blood vessel growth in the retina. The drug showed consistent efficacy regardless of whether patients were concurrently taking GLP-1 medications.

Market Implications:

Kodiak Sciences plans to accelerate its FDA approval submission based on these results, positioning the company to potentially enter the diabetic retinopathy treatment market. Diabetic retinopathy affects diabetes patients and is characterized by damaged retinal blood vessels that can cause leakage, bleeding, and vision loss.

The significant stock price movement reflects strong investor confidence in the drug's commercial potential and the company's pathway to regulatory approval.